COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN

被引：0
|
作者：
Lindgren, P. [1 ]
Hagstrom, E. [2 ]
van Hout, B. [3 ]
Villa, G. [4 ]
Pemberton-Ross, P. [4 ]
Arellano, J. [5 ]
Sibartie, M. [4 ]
Fonarow, G. C. [6 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Uppsala Univ, Uppsala, Sweden
[3] Univ Sheffield, Sheffield, S Yorkshire, England
[4] Amgen Europe GmbH, Rotkreuz, Switzerland
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV40
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF A POLYPILL FOR PATIENTS WITH OR AT HIGH RISK OF CARDIOVASCULAR DISEASE IN AN NHS SETTING
    Crossan, C. J.
    Dehbi, H.
    Thom, S.
    Poulter, N.
    Lord, J.
    VALUE IN HEALTH, 2017, 20 (09) : A620 - A620
  • [22] Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease A Cost-Effectiveness Analysis
    Jarmul, Jamie
    Pletcher, Mark J.
    Lich, Kristen Hassmiller
    Wheeler, Stephanie B.
    Weinberger, Morris
    Avery, Christy L.
    Jonas, Daniel E.
    Earnshaw, Stephanie
    Pignone, Michael
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2018, 11 (04):
  • [23] Cost-Effectiveness Analysis of Evolocumab Therapy in Patients at High Risk of Cardiovascular Events in the Context of the Brazilian Unified Health System
    Latado, Luiza
    Vieira de Melo, Rodrigo Morel
    Mistro, Sostenes
    Latado, Adriana Lopes
    do Nascimento, Harrison Floriano
    Lira, Yasmin Menezes
    Cardoso de Oliveira, Natalia Ferreira
    Galindo, Yuri de Santana
    Viana, Taina
    Santana Passos, Luiz Carlos
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 117 (05) : 988 - 996
  • [24] Cost-effectiveness of Evolocumab. Response
    de Labry Lima, Antonio Olry
    Matas Hoces, Antonio
    Alegre del Rey, Emilio Jesus
    Gimeno Ballester, Vicente
    REVISTA ESPANOLA DE CARDIOLOGIA, 2018, 71 (12): : 1090 - 1090
  • [25] Cost-effectiveness of rosuvastatin for cardiovascular prevention in high-risk populations in Sweden
    Jonsson, L.
    Ekman, M.
    Karlsson, G.
    Brun, J.
    VALUE IN HEALTH, 2006, 9 (06) : A346 - A346
  • [26] Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease
    Rennert-May, Elissa
    Manns, Braden
    Clement, Fiona
    Spackman, Eldon
    Collister, David
    Sumner, Glen
    Leal, Jenine
    Miller, Robert J. H.
    Chew, Derek S.
    CANADIAN JOURNAL OF CARDIOLOGY, 2025, 41 (01) : 128 - 136
  • [27] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION IN CANADA
    Urbich, M.
    Jobin, M.
    Rogoza, R.
    VALUE IN HEALTH, 2020, 23 : S495 - S495
  • [28] Cost-effectiveness of pharmacist care for managing patients at high risk for cardiovascular disease in Canada
    Al Hamarneh, Y. N.
    Johnston, K.
    Marra, C.
    Tsuyuki, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 297 - 298
  • [29] Cost-Effectiveness of Cardiovascular Disease Spending
    Miller, George
    Cohen, Joshua T.
    Roehrig, Charles
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (20) : 2123 - 2124
  • [30] COST-EFFECTIVENESS OF ROSUVASTATIN 10 MG IN THE REDUCTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS AT RISK OF CARDIOVASCULAR DISEASE
    Ohsfeldt, R.
    Gandhi, S. K.
    Jensen, M. M.
    Smolen, L.
    Fox, K. M.
    Gold, A.
    Hsia, J.
    VALUE IN HEALTH, 2010, 13 (03) : A165 - A165
12345